HEIDELBERG, Germany, May 31, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company
focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present
at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 8:30 a.m. (ET) in New York City.
To access a simultaneous webcast of Dr. Hoess' presentation online, log on to http://wsw.com/webcast/jeff97/afmd or go to the "Events" section on the "Media" page of the Affimed website at
http://www.affimed.com/events.php. A replay of the webcast will be available from Affimed's website for
30 days following the conference. Dr. Hoess' presentation will be available for download in PDF format immediately following the
conference presentation in the "Events" section of the Media page of Affimed's website at http://www.affimed.com/events.php.
About Affimed N.V.
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and
adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening
diseases. For more information, please visit www.affimed.com.
CONTACT: IR Contact: Caroline Stewart, Head IR Phone: +1 347394 6793 E-Mail: IR@affimed.com or c.stewart@affimed.com Media Contact: Anca Alexandru, Head of Communications Phone: +49 6221 64793341 E-Mail: a.alexandru@affimed.com